MannKind says HFSA analyses show Furoscix ReadyFlow matches IV furosemide urine output
MNKD•MannKind said clinical analyses presented at HFSA 2026 showed Furoscix ReadyFlow produced diuretic effects comparable to intravenous furosemide, with flexible injection-site use and responses similar to its older on-body infusor.
1. Study findings
MannKind said analyses presented at HFSA 2026 on Oct. 9-12 indicated that its Furoscix ReadyFlow autoinjector delivered diuretic effects comparable to intravenous furosemide and supported flexible injection-site use without loss of performance. Cross-study findings suggested similar responses to the older Furoscix on-body infusor. The update follows FDA clearance in July 2026 and a U.S. launch.
